ENA man has metastatic prostate cancer, hormone treatment no longer holds his PSA down, and the value is rising again. Online, his relatives read about “life-saving immunotherapy” and start looking for a place in Germany to get it.
Immunotherapy is used far less often for prostate cancer than for melanoma or lung cancer, and mostly within clinical trials. This page covers why, who may still benefit, what treatment of metastases rests on today, what the outlook depends on and how to arrange a consultation.
Immunotherapy and prostate cancer: why the tumour responds poorly
The tumour responds poorly because immunotherapy works best on cancers the immune system already “sees”, and prostate cancer is rarely one of them. Its main drugs are checkpoint inhibitors: a tumour presses the “brake” on immune cells to stop their attack, and the drug releases it. This works best where a tumour has many mutations, which make its cells look foreign, and many immune cells.
Doctors call prostate cancer a “cold” tumour: on average it has few mutations, and few immune cells get inside. That is why large trials of checkpoint inhibitors in unselected patients did not show a benefit that changed the standard of care. A separate page covers cancer immunotherapy in general.
Who immunotherapy still suits
Immunotherapy mainly suits a small group of patients whose tumour has microsatellite instability (MSI-high) or a DNA mismatch repair defect (dMMR). Put simply, such a tumour “repairs” its DNA poorly and builds up many mutations that the immune system can notice.
In these cases the decision lies with the tumour board. Drugs of this group are not authorised in the EU for prostate cancer, so this is off-label use, and payment through insurance or privately is settled in advance. The German S3 guideline notes that data on this approach in advanced prostate cancer are still very limited. A cell-based vaccine approved in the USA, sipuleucel-T, is currently not available in Europe: its EU authorisation has been withdrawn.
The practical step is molecular testing of tumour tissue for MSI, BRCA and other repair genes. It shows at once whether immunotherapy or a targeted drug may fit.
Clinical trials: new immune approaches
New immune treatments for prostate cancer are mostly given within trials at university centres. These test bispecific antibodies that bring an immune cell and a tumour cell together, including ones directed at PSMA, a protein on prostate cancer cells; cell-based methods, in which a patient’s immune cells are reprogrammed in the laboratory; and combinations with hormonal drugs. Their benefit is still being studied, so no result can be promised.
For an international patient, inclusion criteria are strict and recruitment may already be closed. The study drug is free, but accompanying costs are not always covered. The hospital’s research team decides based on the records.
What remains the mainstay of treatment
The mainstay remains suppressing testosterone plus newer anti-androgen drugs (abiraterone, enzalutamide, apalutamide or darolutamide), combined with docetaxel chemotherapy for fit patients; immunotherapy does not replace it. While the cancer still responds to lowering testosterone, it is called hormone-sensitive; once it grows despite low testosterone, castration-resistant.
When hormones stop working, the options discussed are PSMA therapy, a radioligand treatment that carries radiation to tumour cells via the PSMA protein, targeted drugs for BRCA mutations and radiotherapy to single lesions. Details by stage and surgery are on the general page on prostate cancer treatment in Germany. The NCI patient information on prostate cancer treatment gives an overview of all options.
What to expect from immunotherapy
In patients selected by MSI or dMMR, the response to immunotherapy can be durable, but it does not happen in everyone. This page gives no average survival figures: they date quickly and say little about an individual. Doctors discuss the outlook only after a complete work-up and look at hormone sensitivity, how far the disease has spread, the PSA response on treatment, tumour aggressiveness on histology and general health.
For the family, the point of a consultation in Germany is not to miss a suitable option, including a clinical trial. We make no promises of outcome.
Frequently asked questions
Is prostate cancer immunotherapy available in Germany?
Yes, but rarely and not for everyone. It is considered when the tumour shows microsatellite instability (MSI-high) or a mismatch repair defect (dMMR); newer immune methods are offered within trials. These drugs are not authorised in the EU for prostate cancer, so the tumour board decides and payment is agreed in advance. Other patients receive hormone treatment, chemotherapy or radioligand therapy.
Which tests show whether immunotherapy suits prostate cancer?
Molecular testing of tumour tissue shows this. It is done on paraffin blocks from a biopsy or surgery and looks for microsatellite instability or a mismatch repair defect, and for mutations in BRCA and other DNA repair genes. The same test shows whether a targeted drug may fit. Bring any earlier report: doctors in Germany will decide whether it is enough.
Can an international patient join a prostate cancer immunotherapy trial?
Yes, if he meets the inclusion criteria and the trial is still recruiting. The hospital’s research team reviews the records first and may ask for extra tests. The study drug is free, but travel, accommodation and other costs are not always covered. Without a suitable trial, the tumour board recommends standard treatment.
How AlenMed arranges prostate cancer consultation and treatment in Germany
Prostate cancer immunotherapy in Germany is only possible after a complete work-up, so it starts with the documents: PSA history with dates, histology with the Gleason score, PSMA PET/CT or a bone scan, a list of all hormonal drugs taken, genetic test results and paraffin blocks. We translate the records and pass them to uro-oncologists at partner hospitals. They include Prof. Georg Bartsch, head of urology at Agaplesion Markus Krankenhaus in Frankfurt and vice chairman of the German Working Group on Castration Resistant Prostate Cancer. Another partner is the Department of Urology at TUM Klinikum rechts der Isar, where Prof. Jürgen Gschwend heads the ProstaTUM prostate centre.
The tumour board decides on treatment or a trial, and the patient receives a written report for doctors at home. We request the hospital cost estimate, arrange the visa invitation and find an interpreter. The page on prostate cancer treatment costs explains what the bill includes. AlenMed’s office is in Munich, and partner hospitals are all over Germany.
This material is for reference only and is not an offer. Whether immunotherapy is an option is decided by a doctor at an in-person consultation and by the tumour board.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
